Company news
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) news
Supernus Pharmaceuticals, Inc. news releases on 6ix. Latest, Feb 22, 2022: Supernus to Provide Preliminary Fourth Quarter and Full Year 2021 Financial Results…
Press releases — page 3
Supernus to Provide Preliminary Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 28, 2022
February 21, 2022
Supernus Receives Notice Assigning Early October 2022 PDUFA for SPN-830 Apomorphine Infusion Device NDA
February 21, 2022
Supernus Pharmaceuticals Targeted in Ransomware Incident
November 23, 2021
Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals
November 23, 2021
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender Offer
November 22, 2021
Supernus to Participate in Annual Piper Sandler Healthcare Conference
November 17, 2021
Supernus to Participate in Upcoming November Investor Conferences
November 9, 2021
Supernus Announces Third Quarter 2021 Financial Results
November 2, 2021
Supernus to Announce Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021
October 26, 2021
Holly Robinson Peete Partners with Supernus to Raise Awareness During ADHD Awareness Month
October 19, 2021
Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio
October 10, 2021
Supernus to Participate in Upcoming September Investor Conferences
September 1, 2021
Supernus Announces Qelbree™ sNDA for Adult Indication Accepted for Review by FDA
September 1, 2021
Supernus Announces Second Quarter 2021 Financial Results
August 3, 2021
Supernus to Host Second Quarter 2021 Financial Results Conference Call
July 21, 2021
Supernus to Present at Jefferies Virtual Healthcare Conference
May 24, 2021
Qelbree™ (viloxazine extended-release capsules), a New Non-Controlled Substance, Now Available for the Treatment of ADHD in Pediatric Patients 6-17 Years of Age
May 23, 2021
Supernus Announces First Quarter 2021 Financial Results
May 4, 2021
Supernus Announces Paragraph IV ANDA Filing for XADAGO®
May 3, 2021
Supernus to Host First Quarter 2021 Financial Results Conference Call
April 26, 2021
Supernus Announces FDA Approval of Qelbree™ (SPN-812) for the Treatment of ADHD
April 1, 2021
Supernus to Present at Cowen Healthcare Conference
February 25, 2021
Supernus Announces Fourth Quarter and Full Year 2020 Financial Results
February 24, 2021
Supernus to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call
February 22, 2021
Supernus Receives FDA Notice Assigning Early April 2021 PDUFA Date for SPN-812 NDA
February 21, 2021
Supernus Resubmits New Drug Application for SPN-812 for the Treatment of ADHD in Pediatric Patients
February 7, 2021
Supernus to Present at J.P. Morgan 39th Annual Healthcare Conference
January 5, 2021
Supernus Announces Positive Results from Phase III Study for SPN-812 in Adults with ADHD
December 21, 2020
Supernus to Present at Two November Investor Conferences
November 10, 2020
Supernus Provides Regulatory Updates for SPN-812 and SPN-830
November 8, 2020
Supernus Announces Third Quarter 2020 Financial Results
November 2, 2020
Supernus to Host Third Quarter 2020 Financial Results Conference Call
October 26, 2020
Supernus Pharmaceuticals Appoints James Kelly as Chief Financial Officer
October 4, 2020
Supernus Submits NDA for SPN-830 for Continuous Treatment of ON-OFF Episodes in Adults with Parkinson’s Disease Who Have Failed Two Treatments
September 13, 2020
Supernus to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
September 8, 2020
Supernus to Present at the Wells Fargo Virtual Health Care Conference
September 1, 2020
Supernus Announces Second Quarter 2020 Financial Results
August 17, 2020
Supernus Announces Preliminary Second Quarter 2020 Revenue
August 10, 2020
Supernus Sues Apotex for Infringement of Oxtellar XR® Patents
June 25, 2020
Supernus Completes Acquisition of CNS Portfolio from US WorldMeds
June 8, 2020
Supernus to Present at the Jefferies Virtual Health Care Conference
May 26, 2020
Supernus Announces Paragraph IV ANDA Filing for Oxtellar XR®
May 14, 2020
Supernus Announces First Quarter 2020 Financial Results
May 4, 2020
Supernus to Acquire CNS Portfolio from US WorldMeds
April 27, 2020
Supernus to Host First Quarter Results Earnings Conference Call
April 23, 2020
Supernus and Navitor Announce Development and Option Agreement for Orally Active mTORC1 Activator NV-5138
April 20, 2020
Supernus Provides Business Update
March 29, 2020
Supernus to Present at the 2020 Cowen Health Care Conference
February 25, 2020
Supernus Announces Fourth Quarter and Full Year 2019 Financial Results
February 24, 2020
Supernus to Host Fourth Quarter and Full Year 2019 Results Earnings Conference Call
February 10, 2020